|Bid||37.00 x 900|
|Ask||60.35 x 1200|
|Day's range||46.49 - 51.58|
|52-week range||10.72 - 79.75|
|Beta (5Y monthly)||1.24|
|PE ratio (TTM)||30.45|
|Earnings date||09 Feb 2022 - 14 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||82.22|
Cassava (SAVA) tanks on reports of an investigation by the SEC related to data reports on its AD candidate.
Prothena misses on earnings and revenues in the third quarter of 2021. Nevertheless, the company's progress with its AD pipeline is encouraging.
Prothena (PRTA) delivered earnings and revenue surprises of -5.33% and -0.64%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?